We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Engagements

MYBOARD is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Insights

MYinSIGHTS provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

MYConference Targeted Reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

NCCN Flash Update: Changes to Colon Cancer Guidelines, Version 3.2025

Source: Pharmacy Times articles NCCN updates colon cancer guidelines, emphasizing testing for DPYD gene variants before initiating fluoropyrimidine-based chemotherapy. Read More

AAN 2025: Low-Sodium Oxybate Improves Sleep Quality, Daily Functioning in Narcolepsy, Idiopathic Hypersomnia

Source: Pharmacy Times articles Logan Schneider, MD, explains the latest findings on narcolepsy and idiopathic hypersomnia treatments, highlighting patient experiences and sleep architecture improvements. Read More

Asembia’s AXS25 Summit: Must-See Sessions, Expert Interviews as Specialty Pharmacy Gathers

Source: Pharmacy Times articles The Asembia AXS25 Summit will include the latest news and expert insights in the specialty pharmacy field. Read More

NCPA Urges DOGE to Examine PBMs for Waste, Fraud, and Abuse

Source: Pharmacy Times articles Government doles out billions to PBMs to stabilize premiums, but premiums keep rising along with PBM profits. Read More

Pyrotinib-Based Therapy May Improve Survival in Patients With HER2+ Breast Cancer and Liver Metastases

Source: Pharmacy Times articles Pyrotinib is a tyrosine kinase inhibitor that is independently developed in China. Read More

Recent Publications

Single-Nucleotide Polymorphisms Related to Multiple Myeloma Risk: A Systematic Review and Meta-Analysis

Int J Mol Sci. 2025 Apr 4;26(7):3369. doi: 10.3390/ijms26073369. ABSTRACT Multiple myeloma ranks...

Unveiling Extramedullary Myeloma Immune Microenvironment: A Systematic Review

Cancers (Basel). 2025 Mar 24;17(7):1081. doi: 10.3390/cancers17071081. ABSTRACT...

Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review

Cancers (Basel). 2025 Apr 5;17(7):1235. doi: 10.3390/cancers17071235. ABSTRACT Background:...

Efficacy and Safety of triplet versus doublet regimens in patients with multiple myeloma: A systematic review and meta-analysis

Curr Probl Cancer. 2025 Apr 3;56:101202. doi: 10.1016/j.currproblcancer.2025.101202. Online ahead...

Efficacy and Safety of Quadruplet Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma: A Systematic Review and Meta-Analysis

Cancer Rep (Hoboken). 2025 Apr;8(4):e70171. doi: 10.1002/cnr2.70171. ABSTRACT BACKGROUND: The...

Email

info@myeloma360.com